Evidence map›Paper›PMID 31533643›Full record

SynthesisBMC infectious diseases2019

Hepatitis B infection in the general population of China: a systematic review and meta-analysis.

Huai Wang, Peixuan Men, Yufeng Xiao, Pei Gao, Min Lv, Qianli Yuan, Weixin Chen, Shuang Bai, Jiang Wu

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04356404 (Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients on Immunosuppressive and Biological Modifier Therapies Exposure), which is not on this map. Cited by 150 papers, 18 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 18 pooled it
20.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04356404 terminatednot on this mapstarted 2020, after this paper: background citation

Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients on Immunosuppressive and Biological Modifier Therapies Exposure

TypeobservationalSponsorChinese University of Hong KongRan2020 to 2022Enrolled68ConditionsOccult Hepatitis B, Biological Substance, Adverse Effect, Immunosuppression
3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 18 syntheses or guidelines pooled it, 263 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Systematic analysis of acute liver injury during SARS-CoV-2 infection.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2020
    Pooled it
  18. Pooled it
  19. Trial
  20. Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Huai WangInstitute for immunization and prevention, Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, No.16, HePingLi Middle Street, DongCheng District, Beijing, 100013, China.
Peixuan MenChina Institute of Medical Information/Medical Library, CAMS&PUMC, No. 69 Dongdan North Street, Dongcheng District, Beijing, 100005, China.
Yufeng XiaoChina Institute of Medical Information/Medical Library, CAMS&PUMC, No. 69 Dongdan North Street, Dongcheng District, Beijing, 100005, China.
Pei GaoInstitute for immunization and prevention, Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, No.16, HePingLi Middle Street, DongCheng District, Beijing, 100013, China.
Min LvInstitute for immunization and prevention, Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, No.16, HePingLi Middle Street, DongCheng District, Beijing, 100013, China.
Qianli YuanInstitute for immunization and prevention, Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, No.16, HePingLi Middle Street, DongCheng District, Beijing, 100013, China.
Weixin ChenInstitute for immunization and prevention, Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, No.16, HePingLi Middle Street, DongCheng District, Beijing, 100013, China.
Shuang BaiInstitute for immunization and prevention, Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, No.16, HePingLi Middle Street, DongCheng District, Beijing, 100013, China.
Jiang WuInstitute for immunization and prevention, Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, No.16, HePingLi Middle Street, DongCheng District, Beijing, 100013, China. wj81732@hotmail.com.
Beijing Center for Disease Prevention and Control · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

Beijing Science and Technology Planning Project D171100003117001
6 · The paper itself

Abstract

backgroundHepatitis B virus (HBV) infection is a major public health problem in China. Over a decade has passed since the last National Hepatitis Seroepidemiological Survey was conducted in 2006. The lack of updated data on hepatitis B in China makes assessing the current prevalence and burden of the disease inadequate. In response to the above situation, a systematic review and meta-analysis was conducted to provide a better understanding of hepatitis B epidemiology in the general population of China.

methodsA systematic search was conducted in international databases (Medline through PubMed, EMBASE, Cochrane, Web of Science) and national databases (CBM, CNKI, WanFang Data) to retrieve primary studies published between January 1, 2013 and December 31, 2017. The pooled prevalence of HBV infection and 95% confidence intervals were calculated. Quality assessment, heterogeneity testing and publication bias assessment were also performed.

resultsOf the 27 studies included in the meta-analysis, the pooled estimated prevalence of HBV infection in the general population of China from 2013 to 2017 was 6.89% (95% CI:5.84-7.95%), which could be extrapolated to an estimated population of 84 million living with HBsAg in 2018. The prevalence of HBV infection in males was higher than that in females (5.88% vs 5.05%), and rural areas had a higher prevalence than urban areas (5.86% vs 3.29%). The highest prevalence of HBV infection was reported in Western provinces (8.92, 95% CI: 7.19-10.64%). In adults older than 20 years, the prevalence of HBV infection was approximately 7%, which was higher than that in children.

conclusionThe prevalence of HBV infection in the general population of China was classified as higher intermediate prevalence (5-7.99%), of which more than 90% of the HBV infection population included adults older than 20 years. The blocking of mother-to-infant hepatitis B transmission and plans involving timely birth dose of hepatitis B vaccine within 24 h should be implemented. Additionally, improving the quality of life and survival rate of the infected population through antiviral therapy and high-risk adult vaccination will be the priority of our future work. Moreover, various control measures should be implemented in different provinces across China.

Indexed as

Age FactorsChinaDatabases, FactualHepatitis BHepatitis B Surface AntigensHumansPrevalenceUrban PopulationHepatitis B Surface AntigensChinaHepatitis BMeta-analysisPrevalence

Identifiers

PMID31533643
PMCPMC6751646
OpenAlexW2974194331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.